Pipeline

Target
Selection
Lead
Generation
Lead
Optimisation
Pre-clinical
POC
CTA / IND Phase I Phase II

Oncology

Porcupine inhibitor
Porcupine inhibitor
Porcupine inhibitor
Porcupine inhibitor
Into Phase I mid 2017

Redx is developing novel inhibitors of Porcupine, a key component of the Wnt cancer stem cell pathway. Potential opportunities exist for the treatment of breast, pancreatic, head and neck cancers.

BTK inhibitor
BTK inhibitor
BTK inhibitor
Into Phase I late 2017

Redx is developing best-in-class reversible inhibitors of BTK for the treatment of Ibrutinib resistant chronic lymphocytic leukaemia.

IDO inhibitor
IDO inhibitor
IDO inhibitor

Redx is developing novel inhibitors of IDO, a pathway active in many cancers. Potential treatment opportunities include solid tumours such as skin and lung cancers.

Pan-Raf inhibitor
Pan-Raf inhibitor
Pan-Raf inhibitor

Redx is developing novel small molecule therapeutics with combined activity against different Raf isoforms. These novel compounds target mechanisms of resistance associated with existing MAPK pathway inhibitors in conditions such as colorectal cancer.

AstraZeneca Collaboration
AstraZeneca Collaboration
AstraZeneca Collaboration
AstraZeneca Collaboration

Redx and AstraZeneca are collaborating on an undisclosed target for cancer therapy.

SHP2
SHP2

Redx is developing novel SHP2 inhibitors for the treatment of several difficult to treat solid tumour types.

Immunology

Porcupine inhibitor
Porcupine inhibitor
Porcupine inhibitor
Porcupine inhibitor

Redx is developing best-in-class irreversible and reversible inhibitors of BTK for the treatment of autoimmune and inflammatory disorders such as rheumatoid arthritis, lupus and Sjögren's syndrome.

BTK inhibitor
BTK inhibitor
BTK inhibitor

Redx is developing best-in-class irreversible and reversible inhibitors of BTK for the treatment of autoimmune and inflammatory disorders such as rheumatoid arthritis, lupus and Sjögren's syndrome.

ROCK2
ROCK2

Redx is developing best-in-class selective inhibitors of ROCK2 for the treatment of a range of fibrotic diseases.

Anti-Inf.

MDR Gram-negative*
MDR Gram-negative*
MDR Gram-negative*
MDR Gram-negative*

Gram-negative bacteria include E. coli and Pseudomonas. Redx is developing antibiotics against multi-drug resistant Gram-negative bacteria, with the potential opportunities to treat urinary tract infections, pneumonia and intra-abdominal infections.

Target
Selection
Lead
Generation
Lead
Optimisation
Pre-clinical
POC
CTA / IND Phase I Phase II

Last updated 21/03/17

* Will only be progressed in collaboration with a partner